Nurix Therapeutics Chief Scientific Officer Gwenn Hansen Reports Disposal of $142,900.9987 in Common Shares

• Nurix Therapeutics Chief Scientific Officer Gwenn Hansen sold 3,957 common shares at $26.2791 on Oct. 30, 2026.
• Hansen also acquired 10,182 common shares at $0 through restricted stock unit conversions on Oct. 30.
• On Nov. 2, 2026, Hansen exercised options for 1,452 shares at $1.86, selling those shares at $26.8.
• Direct beneficial ownership stood at 123,452 common shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001817160-26-000023), on November 02, 2026, and is solely responsible for the information contained therein.